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Abstract
Background: Thalidomide is an inhibitor of tumour necrosis factor-alpha (TNFα) that has been
proven effective for the treatment of experimental sepsis by Escherichia coli. It was tested whether
it might behave as an effective immunomodulator in experimental sepsis by multidrug-resistant
(MDR) Pseudomonas aeruginosa.
Methods: Sepsis was induced by the intraperitoneal injection of 1 × 108 cfu/kg inoculum of the test
isolate in a total of 109 Wistar rats divided in three groups as follows: group A controls; group B
administered seed oil 30 minutes before bacterial challenge; and group C administered 50 mg/kg of
thalidomide diluted in seed oil 30 minutes before bacterial challenge. Blood was sampled for
estimation of endotoxins (LPS), TNFα, interferon-gamma (IFNγ), nitric oxide (NO) and
malondialdehyde (MDA). LPS was measured by the QCL-1000 LAL assay, TNFα and IFNγ by ELISA,
NO by a colorimetric assay and MDA by the thiobarbiturate assay.
Results: Mean (± SE) survival of groups A, B and C were 18.60 ± 1.84, 12.60 ± 0.60 and 30.50 ±
6.62 hours (p of comparisons A to C equal to 0.043 and B to C equal to 0.002). Decreased TNFα
and NO levels were found in sera of animals of group C compared to group A. Plasma levels of
LPS, MDA and IFNγ did not differ between groups.
Conclusion: Intake of thalidomide considerably prolonged survival in experimental sepsis by MDR
P.aeruginosa an effect probably attributed to decrease of serum TNFα.
Background
Nosocomial infections are commonly caused by multid-
rug-resistant Gram-negative pathogens. Management of
these infections is difficult due to the lack of potent anti-
microbial agents; thus a target for immunomodulatory
intervention is created [1]. Thalidomide is an old regimen
that has been proved potent in reducing the half-life of
mRNA of the gene of tumour necrosis factor-alpha
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(TNFα) in human monocytes [2]. Its anti-angiogenic and
anti-TNFα properties have led to its application for the
treatment of erythema nodosum leprosum, of cutaneous
lupus erythematosus, of Behçet's syndrome, of multiple
myeloma and of HIV-related aphthous ulcers and wasting
syndrome [3,4].
In a model of experimental sepsis by Escherichia coli, tha-
lidomide was proved very effective in reducing serum lev-
els of TNFα, a phenomenon that was associated with
refraining of evolution to sepsis [5]. However, its effect on
survival was not assessed. The immunomodulatory bene-
fit of thalidomide would be of considerable importance
for sepsis induced by multidrug-resistant isolates. The
present study was designed to evaluate thalidomide in
experimental sepsis by multidrug-resistant Pseudomonas
aeruginosa. Interest was focused on the effect of thalido-
mide on a) survival after bacterial challenge, and b) serum
levels of pro-inflammatory mediators.
Methods
Animals
A total of 109 male Wistar rats were enrolled in the study.
Their mean (± SD) weight were 257.2 ± 40.2 g. The study
received permit from the Veterinary Directorate of the Per-
fecture of Athens according to the Greek legislation in
conformance to the Council Directive of the European
Community. Rats were housed in metal cages and had
access to tap water and standard balanced chow ad libitum.
Temperature ranged between 18 and 22°C, relative
humidity between 55 and 65% and the light/dark cycle
was 6 am/6 pm.
Bacterial isolate
One multidrug-resistant blood isolate of P. aeruginosa
derived from a patient with nosocomial sepsis was
applied. Minimal inhibitory concentrations (MICs) of
ticarcillin/clavulanate, piperacillin, ceftazidime, imi-
penem, meropenem, ciprofloxacin and amikacin were
determined by a microdilution technique of a 0.1 ml final
volume. MIC was considered as the lowest concentrations
of the tested antimicrobial limiting visible bacterial
growth after 18 hours of incubation at 35°C. The isolate
was stored as multiple aliquots in skim milk (Oxoid Ltd,
London, UK) under -70°C. One aliquot was removed
from the fridge before each experiment. Single colonies
were incubated at 37°C in 10 ml of Mueller-Hinton broth
(Oxoid Ltd) for eight hours to yield a log-phase inoculum
that was applied for bacterial challenge.
Study design
Animals were divided into three groups of treatment, as
follows:
• Group A (n = 40), controls; in 20 of these animals sur-
vival was recorded after bacterial challenge and 20 were
sacrificed five hours after bacterial challenge.
• Group B (n = 20), animals pre-treated with linseed oil
30 minutes before bacterial challenge; survival was then
recorded.
• Group C (n = 49), animals pre-treated with thalidomide
30 minutes before bacterial challenge; survival was
recorded for 24 and another 25 were sacrificed five hours
after bacterial challenge.
Thalidomide was supplied as a white amorphous powder
(ICN Biomedicals GmbH, Thüringer, Germany) insoluble
in water. It was diluted in commercial linseed oil and it
was administered via a gastric tube in animals of group C
at a dose of 50 mg/kg, based on previous results [5]. The
respective dose of linseed oil administered was 2 ml/kg.
The same dose was administered in animals of group B. A
1 × 108 cfu/kg inoculum of the test isolate was injected
intraperitoneally in all animals.
Survival was recorded at 12-hour time intervals. Five
hours after bacterial challenge, a midline abdominal inci-
sion was performed. Intestines were displaced to the left
and the inferior vena cava was recognized and punctured
with a 19-gauge needle. Ten ml of blood was collected
into pyrogen-free syringes and applied for culture and for
the estimation of endotoxins (LPS), of tumour necrosis
factor-alpha (TNFα), of interferon-gamma (IFNγ), of
nitric oxide (NO) and of malondialdehyde (MDA). Ani-
mals were then sacrificed by an intramuscular injection of
pentothal. The 5-hour time interval was selected as the
most appropriate for blood sampling after estimation of
pro-inflammatory mediators in groups of animals inocu-
lated by the test pathogen with hourly time differences
between each sampling (data not shown).
Blood culture and estimation of LPS, cytokines, NO and 
MDA
One ml of blood was added into flasks with growth
medium (Becton Dickinson, Cockeysville, Md) and incu-
bated at 35°C for a total of seven days. Identification of
Gram-negative isolates from blood cultures was made by
the API20NE test (bioMérieux, Paris, France).
Sampled blood was added into pyrogen-free tubes (Vacu-
tainer, Becton Dickinson), and centrifuged; serum was
kept refrigerated as multiple aliquots at -70°C until
assayed. For the determination of LPS, serum was diluted
1:10 with pyrogen-free water (BioWhitaler, Maryland,
USA) and incubated for five minutes at 70°C. LPS were
then measured by the QCL-1000 LAL assay (BioWhitaker,
Maryland, USA, lower detection limit 1 EU/ml). TNFαBMC Infectious Diseases 2005, 5:51 http://www.biomedcentral.com/1471-2334/5/51
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and IFNγ were estimated in serum by an enzymoimmu-
noassay (Diaclone, Paris, France). Lower detection limits
for TNFα and IFNγ were 10 and 10 pg/ml respectively. All
determinations were performed in duplicate.
Nitric oxide (NO) was estimated in serum samples by a
colorimetric assay based on the production of velvet color
after sequential addition of NADH and nitrate reductase
(Assay Designs Inc., Ann Arbor Minnesota, USA). Optical
density was read at 570 nm (Hitachi Spectrophotometer).
Lipid peroxidation in serum was assessed by the estima-
tion of the concentration of malondialdehyde according
to the thiobarbiturate assay, as already described [6,7].
Briefly, a 0.1 ml aliquot of each sample was mixed to 0.9
ml of trichloroacetic acid 20% (Merck, Darmstadt, Ger-
many) and centrifuged at 12,000 g and 4°C for 10 min-
utes. The supernatant was incubated with 1 ml of PBS
(pH: 7.2) and 1 ml of thiobarbituric acid 0.6% (Merck)
for 20 minutes at 90°C. Optical density was then read at
535 nm (Hitachi Spectophotometer). MDA was deter-
mined in mM by a standard curve created with 1, 1, 3, 3-
tetramethoxy-propane (Merck). A water sample treated in
the same way was applied as a blank. All determinations
were performed in duplicate.
Animal sacrifice was not performed for the estimation of
pro-inflammatory mediators in animals of group B. That
was based on the similar survival rate (see below) of
groups A and B.
Statistical analysis
Survival of each group was estimated by Kaplan-Meier
analysis; comparisons between different groups were per-
formed by the log-rank test.
Concentrations of LPS and of serum pro-inflammatory
parameters were expressed by their mean (± SE). Compar-
isons between groups A and C were performed by the
Mann-Whitney U test. Any value of P equal to or below
0.05 was considered as significant.
Results
MICs of ticarcillin/clavulanate, piperacillin, ceftazidime,
imipenem, meropenem, ciprofloxacin and amikacin for
the test isolate were >256/4, >256, 16, 16, 16, >256 and
>512 µg/ml respectively.
Mean (± SE) survival of group A was 18.60 ± 1.84 hours,
of group B 12.60 ± 0.60 hours (P: 0.036 compared to
group A) and of group C 30.50 ± 6.62 hours (P equal to
0.043 when compared to group A and equal to 0.002
when compared to group B). Survival curves of each group
of treatment are given in Figure 1. Survival of one animal
of group C was prolonged to 168 hours. After subtraction
of that animal, the mean (± SE) survival of group C was
24.52 ± 2.97 hours (P equal to 0.049 when compared to
group A and equal to 0.004 when compared to group B).
No diarrhea was noted over follow-up of groups B and C.
All animals had positive blood cultures. Comparisons of
serum pro-inflammatory mediators of groups A and C
estimated five hours after bacterial challenge are given in
Table 1. Mean LPS levels of groups A and C were 13.12
and 13.52 EU/ml respectively. Respective values of TNFα
were 153.9 and 74.7 pg/ml, of IFNγ 782.4 and 564.4 pg/
ml, of NO 1,694.4 and 618.9 µM, and of MDA 4.30 and
4.564 mM respectively.
Discussion
The perspective of an immunomodulatory intervention in
sepsis, as evolved from human studies with the applica-
tion of monoclonal antibodies, was very promising. How-
ever the application of these antibodies in clinical practice
failed to disclose particular benefit [8,9]. The need of such
immunotherapies seems to be increasing for the field of
nosocomial infections where the availability of antimicro-
bial agents is limited. Thalidomide has been proved effec-
tive in reducing serum TNFα in experimental sepsis
induced by endotoxins [10,11] and E.coli [5] by a mecha-
nism differing from monoclonal antibodies. The present
study documented the effect of thalidomide in an experi-
mental model simulating a nosocomial infection ie sepsis
by multidrug-resistant P.aeruginosa. This is the first time,
to our knowledge, that an agent with anti-TNFα proper-
ties is applied in an experimental model of sepsis triggered
by a multidrug-resistant pathogen.
The applied model of sepsis was lethal as documented by
the absolute mortality rate of animal-controls. Results
revealed a considerable benefit of thalidomide intake on
survival after bacterial challenge (Figure 1). Animals
administered only the vehicle of thalidomide died earlier
than controls a phenomenon aggravating the potency of
thalidomide. Bacteremia and endotoxemia were equally
present in all groups of treatment (Table 1) so that all ani-
mals had the same chance of evolution to sepsis. Thalido-
mide prolonged survival even in the presence of
considerable endotoxaemia.
The action of thalidomide seems to be mediated by degra-
dation of the mRNA of TNFα and probably of IFNγ [12].
In the present study, intake of thalidomide was accompa-
nied by significant decrease of serum TNFα and of NO
whereas serum levels of MDA and of IFNγ remained unaf-
fected (Table 1). Its specific anti-TNFα effect has also been
considered as the mode of action in experimental sepsis
by E.coli [5]. Biosynthesis of NO is triggered by TNFα [13],
so that decrease of NO following that of TNFα might beBMC Infectious Diseases 2005, 5:51 http://www.biomedcentral.com/1471-2334/5/51
Page 4 of 5
(page number not for citation purposes)
Comparative survival of Wistar rats after bacterial challenge with multidrug-resistant Pseudomonas aeruginosa Figure 1
Comparative survival of Wistar rats after bacterial challenge with multidrug-resistant Pseudomonas aeruginosa. Group A: con-
trols; group B: rats pre-treated with seed oil; and group C: rats pre-treated with thalidomide.
Table 1: Comparison of serum concentrations of endotoxins (LPS), nitric oxide (NO), malondialdehyde (MDA), tumour necrosis 
factor-alpha (TNFα) and interferon-gamma (IFNγ) of animals-controls (group A) and of animals pre-treated with thalidomide (group 
C) sacrificed five hours after bacterial challenge.
Group A Group C p
Mean ± SE
LPS (EU/ml) 13.12 ± 0.17 13.52 ± 0.44 NS
NO (µM) 1,694.4 ± 400.9 618.9 ± 350.3 0.009
MDA (mM) 4.30 ± 1.51 4.56 ± 0.54 NS
TNFα (pg/ml) 153.9 ± 53.8 74.7 ± 22.5 0.012
IFNγ (pg/ml) 782.4 ± 103.2 564.4 ± 116.5 NSPublish with BioMed Central    and   every 
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expected. Thalidomide intake did not influence serum
levels of MDA and of IFNγ. MDA is the end product of the
peroxidation of cell membrane lipids occurring during the
septic cascade; lipid peroxidation is triggered by a variety
of pro-inflammatory mediators [14,15]. The specific
blockade of TNFα and not of any other cytokine by thalid-
omide might be consistent with its failure to affect lipid
peroxidation. The latter observation is also consistent
with the observation that thalidomide did prolong sur-
vival but that all animals eventually died (Figure 1). How-
ever, it should be mentioned that the activity of
thalidomide might be mediated by other pathways differ-
ent than inhibition of TNFα.
Conclusion
The present study revealed that intake of thalidomide con-
siderably prolonged survival in experimental sepsis by
multidrug-resistant P.aeruginosa an effect probably attrib-
uted to decrease of serum TNFα. These findings probably
merit further research in order to elucidate their clinical
relevance.
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